Paperwork General Expectations Home Health Care Healthcare Access Now - Free Adult Health Care Coordination for patients with CAD, COPD, DM2, CHF, or HTN who are on Buckeye or Caresource Insurance
Chapters: 00:00 Intro & Team Shoutouts02:20 Hiring Strengths vs Weaknesses06:00 Warrior Makers Meetup Idea08:30 Hyperhidrosis & Botox Solution12:00 Female Fat Loss & Muscle Stack18:20 HGH vs Tessa for Women19:45 Mitochondria Stack Timing (SS-31, MOTS-C)23:30 Peptides for Muscle Growth (60+)26:30 Peptide Mixing & Syringe Basics35:20 Parkinsons, Dementia & Healing Peptides41:30 Hashimotos, Diet & KPV/BPC46:00 Hair Transplant Protocol & Recovery54:20 IGF-1, MK-677 & Muscle Growth59:20 Weight Loss Plateau & Retatrutide1:06:20 TRT, HCG & Hormone Support1:07:40 Alcohol, Retatrutide & Dopamine Effects We Cover: Hair Transplants: Recovery protocols, healing peptides, and what actually works post-surgery Excessive Sweating: Why Botox beats peptides for hyperhidrosis Female Fat Loss: Tesa vs Tesa/Ipa, water retention, and dialing in results Muscle Building (Women): IGF-1, creatine, and realistic expectations Menopause Support: NAD+, MOTS-C, SS-31, GHK-CU, and when to use HGH Mitochondrial Health: SS-31 vs MOTS-C timing and stacking with 5-Amino Muscle Growth Truth: Why peptides arent enough without TRT, HGH, and nutrition Dosing Mistakes: Units, reconstitution, and fixing common injection errors Fat Loss Plateaus: Using RETA + SLU-PP-332 to break stalls Metabolism Issues: How muscle loss slows fat loss TRT Optimization: Why adding HCG still matters long-term Eczema & Inflammation: Peptide options for gut and skin support Brain Health: Peptides for cognitive decline and neurological support Autoimmune Issues: Hashimotos, TA1 risks, and gut-first strategies IGF-1 Dosing: Where to start and how to scale Nutrient Timing: Using carbs to drive muscle growth Alcohol & RETA: Why it kills the buzz and slows fat loss Fat Loss Killers: Cortisol, muscle breakdown, and why cutting alcohol matters Subscribe for weekly, no-fluff protocols, dosing guidance, and real-world results
Here are the key milestones: Whats Next: GLP-1 Outlook for 2027 and Beyond The GLP-1 landscape is evolving rapidly
doi:10.3390/jcm12010145
In most cases, we can treat eye complications while you continue your medication, though dose adjustments may be appropriate in specific circumstances
